Objective Tissue calcifications or calcinosis have been described to occur in a variety of systemic autoimmune diseases, even being a significant part of the clinical picture for example in systemic ...

Background Anti-nuclear antibodies (ANA) are common in systemic rheumatic diseases, non-rheumatic autoimmune diseases and the general population. In clinical practice, testing for ANA can inform ...

Background The current recommendations for the treatment of LN consider as the standard of care (SoC) the use of MMF or CYC. Considering the expanding evidence for using calcineurin inhibitors (CNI) ...

Case 1: Blisters in systemic lupus erythematosus Skin lesions can be very heterogeneous in systemic lupus erythematosus (SLE). Clinicopathological correlation is crucial to identify the type of ...

Background/ Purpose Belimumab was approved for the treatment of non-renal SLE in 2011 and has been previously associated with a lower risk of damage progression when compared with prior ‘usual care.’ ...

Inclusion of patient-reported outcomes is important in SLE clinical trials as they allow capture of the benefits of a proposed intervention in areas deemed pertinent by patients. We aimed to compare ...

Objective We performed a scoping review of randomised clinical trials (RCTs) assessing pharmacological therapies for the initial management of lupus nephritis (LN), focusing on study design, included ...

Objective Anifrolumab is a fully human immunoglobulin G 1 κ monoclonal antibody specific for subunit 1 of the type I interferon (IFN) α receptor. In a phase IIb study of adults with moderate to severe ...

Objective Cognitive dysfunction in SLE is common, but clinical risk factors are poorly understood. This study aims to explore the associations of cognitive dysfunction in SLE with disease activity, ...

Conclusions The favourable safety profile and encouraging clinically significant effects noted in some of the endpoints support the need for additional longer term Edratide studies that incorporate ...

Objective To evaluate safety and mechanism of action of mezagitamab (TAK-079), an anti-CD38 monoclonal antibody, in patients with moderate to severe systemic lupus erythematosus (SLE).

Objective Traditional initial treatment regimens for lupus nephritis (LN) used oral glucocorticoids (GC) in starting doses up to 1.0 mg/kg/day prednisone equivalent with or without a preceding ...